search

Active clinical trials for "Liver Neoplasms"

Results 1091-1100 of 1144

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases...

Colorectal Liver Metastases

Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.

Completed2 enrollment criteria

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Liver TumorsHepatocellular Carcinoma2 more

This is an interdisciplinary study that falls into the Humanitarian Use Device category. There are no hypotheses to be tested in this treatment protocol. The study has the following objectives: Provide supervised access to treatment with TheraSphere® to eligible patients with primary cancer to the liver who are not surgical resection candidates. Evaluate patient experience and toxicities associated with TheraSphere® treatment. Measure tumor response rates

Completed20 enrollment criteria

Impact of Sarcopenia on Postoperative Outcomes of Patients Undergoing Liver Resection

Liver NeoplasmsSarcopenia1 more

The investigators will investigate the impact of different biometric parameters (Body mass index, sarcopenia, lean muscle mass, hand-grip strength, gait speed, fat composition) on the postoperative outcomes of patients undergoing liver resections. Major and minor liver resections will be considered as well as open and minimally invasive techniques. Benign and malignant indications will be included. Patients characteristics and perioperative variables will be considered for analysis. Short-term outcomes will be evaluated focusing on 90-days morbidity and mortality and readmission rate.

Completed8 enrollment criteria

Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver...

Pancreatic Ductal AdenocarcinomaWho Have High CTCs Count in Portal Venous Blood1 more

Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer

Unknown status2 enrollment criteria

PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in...

HepatoblastomaHepatic Hemangioendothelioma

Although hepatic tumors are uncommon in the perinatal period they are associated with significant morbidity and mortality in affected patients. The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II) combining with alpha-fetoprotein in hepatic tumor of infant. This study is a multicenter study joined by several hospitals in China. Participants including hepatoblastoma, hepatic hemangioendothelioma and healthy control are consecutively recruited into the cohort. All the serum samples are collected before and after each treatment and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II, alpha-fetoprotein and biochemical indexes including alanine aminotransferase(ALT), aspartate aminotransferase(AST), gamma-glutamyl transferase(GGT), alpha-l-fucosidase(AFU), etc.

Completed6 enrollment criteria

CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases

Liver NeoplasmsLiver/Hepatobiliary Cancer4 more

Contrast-enhanced intraoperative ultrasound (CE-IOUS) plays an increasingly important role in the surgical therapy planning of primary liver lesions as well as liver metastases. The present study was designed to evaluate the significance of CE-IOUS by specificity and sensitivity and particularly the impact it exerts on the surgical strategy. A secondary aim was assessing the outcome relevance of surgeries influenced by CE-IOUS.

Completed7 enrollment criteria

Liver CT Dose Reduction With Deep Learning Based Reconstruction

Radiation ExposureLiver Cancer

A deep learning-based de-noising (DLD) reconstruction algorithm (ClariCT.AI) has the potential to reduce image noise and improve image quality. This capability of the CliriCT.AI program might enable dose reduction for contrast-enhanced liver CT examination. In this prospective multicenter study, whether the ClariCT.AI program can reduce the noise level of low-dose contrast-enhanced liver CT (LDCT) data and therefore, can provide comparable image quality to the standard dose of contrast-enhanced liver CT (SDCT) images will be evaluated. The aim of this study is to compare image quality and diagnostic capability in detecting malignant tumors of LDCT with DLD to those of SDCT with MBIR using the predefined non-inferiority margin.

Completed4 enrollment criteria

Assessment of Frailty in Patients With Advanced Hepatocellular Cancers

Hepatocellular Cancer

This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.

Completed7 enrollment criteria

Evaluation of Preoperative Investigations in Patients With Liver Cancer

Primary Liver CancerLiver Metastasis

The aim of the study is to evaluate the diagnostic procedures emission tomography in combination with a CT scan (PET/CT) and endoscopic ultrasonography (EUS) in the preoperative evaluation of resectability of patients with primary or secondary liver cancers.

Completed8 enrollment criteria

PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA)

Liver NeoplasmsLocal Neoplasm Recurrence

The primary objective of this study is to evaluate the ability of PET-MRI and to detect a local site recurrence during the first year of follow-up after RFA or MWA of colorectal liver metastases (CRLM) as compared with contrast enhanced (ce) CT and PET-CT. Standard reference will be clear focal uptake in the rim of the lesion on PET-CT, possibly in combination with histology (when available) or clinical follow-up. Secondary outcomes are the inter-observer variability, the ability to diagnose new intrahepatic lesions and in what way PET-MRI is able to influence future treatment compared to PET-CT and ceCT. The patients satisfaction concerning the PET-MRI will be examined with a questionnaire.

Completed26 enrollment criteria
1...109110111...115

Need Help? Contact our team!


We'll reach out to this number within 24 hrs